Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Saved in:
Bibliographic Details
Title: Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Authors: Burton EM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tetzlaff MT; Department of Pathology, The University of California San Francisco, San Francisco, CA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Postow MA; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; University of Colorado Cancer Center, Aurora, CO., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Betof Warner A; Stanford University School of Medicine, Stanford University, Stanford, CA., Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., Fisher SB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Song A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Malke J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Simon JM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ariyan C; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Torres-Cabala CA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lazar A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wargo JA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Sep 10; Vol. 43 (26), pp. 2856-2862. Date of Electronic Publication: 2025 Jul 10.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO-25-00494